David Wise, MD Discusses Pasritamig Plus Docetaxel in mCRPC Treatment

Dr. David R. Wise, a genitourinary medical oncologist at NYU Langone Health and associate professor of medicine and urology at the NYU Grossman School of Medicine, has discussed the potential role of combining pasritamig with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Pasritamig is an investigational bispecific T-cell engager designed to target prostate-specific membrane antigen (PSMA) and CD3, aiming to redirect T cells to destroy cancer cells expressing PSMA. Docetaxel is a chemotherapy agent commonly used in the treatment of advanced prostate cancer.

According to Dr. Wise, data from a phase 1b clinical trial evaluating pasritamig in combination with docetaxel showed promising efficacy and safety signals in patients with mCRPC, supporting further investigation in a phase 3 study.

The phase 1b study assessed the combination regimen in patients whose disease had progressed despite prior hormonal therapies, including those who may have received prior taxane-based chemotherapy. Early results indicated antitumor activity, with some patients demonstrating reductions in prostate-specific antigen (PSA) levels and radiographic progression-free survival.

Safety monitoring in the trial revealed a manageable profile, with adverse events consistent with those expected from either agent alone. The most frequently reported side effects included fatigue, nausea, and neutropenia, though no unexpected toxicities were observed that would preclude continued development.

Based on these findings, the investigational regimen has advanced into a phase 3 clinical trial to definitively evaluate whether the addition of pasritamig to standard docetaxel improves overall survival or other meaningful clinical endpoints compared to docetaxel alone in men with mCRPC.

Dr. Wise emphasized that while early-phase data are encouraging, the true therapeutic value of the combination will depend on the outcomes of the ongoing phase 3 study, which aims to enroll a larger, more diverse patient population to assess both efficacy and long-term safety.

He also noted that targeting PSMA with immunotherapeutic approaches like pasritamig represents a growing area of interest in prostate cancer research, particularly as scientists seek to overcome resistance to existing hormonal and chemotherapeutic strategies.

As of now, pasritamig remains an investigational agent and has not received regulatory approval for any indication. Its use is confined to clinical trial settings, and patients interested in participating should consult with their oncologists about eligibility for ongoing studies.

The development of pasritamig plus docetaxel reflects broader efforts to integrate novel immunotherapies with established chemotherapy backbones in the treatment of advanced prostate cancer, with the hope of improving outcomes for patients who have limited therapeutic options.